Conversely, ganitumab was reported to be ineffective in sensitizing patients with KRAS-mutant colorectal cancer to folinic acid, fluorouracil and irinotecan (FOLFIRI) chemotherapy [59]. The gene discussed is KRAS; the disease is colorectal cancer.